Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial (Q29618031)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18653228%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

title

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial (English)

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=18653228

30 April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18653228%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

main subject

phase III clinical trial

0 references

0 references

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18653228%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Camillo Porta

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18653228%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Alain Ravaud

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18653228%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

author name string

Bernard Escudier

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18653228%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Stéphane Oudard

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18653228%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Thomas E Hutson

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18653228%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Sergio Bracarda

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18653228%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Viktor Grünwald

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18653228%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

John A Thompson

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18653228%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Robert A Figlin

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18653228%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Norbert Hollaender

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18653228%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Gladys Urbanowitz

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18653228%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

William J Berg

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18653228%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Andrea Kay

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18653228%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

David Lebwohl

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18653228%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

RECORD-1 Study Group

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18653228%20AND%20SRC:MED&resulttype=core&format=json

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=18653228

11 January 2020

language of work or name

1 reference

30 April 2017

publication date

22 July 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18653228%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=18653228

30 April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18653228%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

volume

372

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=18653228

30 April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18653228%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

page(s)

449-456

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18653228%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

issue

9637

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=18653228

30 April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18653228%20AND%20SRC:MED&resulttype=core&format=json

The von Hippel-Lindau tumor suppressor gene and kidney cancer

11 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961039-9

7 January 2021

Renal-cell carcinoma--molecular pathways and therapies.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961039-9

7 January 2021

TSC2 regulates VEGF through mTOR-dependent and -independent pathways

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961039-9

7 January 2021

Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961039-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961039-9

1 reference

7 January 2021

Immunotherapy for advanced renal cell cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961039-9

7 January 2021

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961039-9

7 January 2021

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961039-9

7 January 2021

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961039-9

7 January 2021

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961039-9

7 January 2021

Targeted therapy for advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961039-9

7 January 2021

Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961039-9

7 January 2021

Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961039-9

7 January 2021

Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961039-9

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961039-9

7 January 2021

Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961039-9

7 January 2021

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961039-9

7 January 2021

Development and validation of a scale to measure disease-related symptoms of kidney cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961039-9

7 January 2021

A Multiple Testing Procedure for Clinical Trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961039-9

7 January 2021

End points and United States Food and Drug Administration approval of oncology drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961039-9

7 January 2021

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961039-9

7 January 2021

10.1016/S0140-6736(08)61039-9

Identifiers

DOI

3 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=18653228

30 April 2017

Consolidated OpenCitations Corpus – April 2017

19195

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18653228%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

19195

1 reference

Consolidated OpenCitations Corpus – April 2017

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=18653228

3 references

30 April 2017

Consolidated OpenCitations Corpus – April 2017

19195